Latest news
RBC Capital Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - MoomooMoomoo · Sat, 08 Aug 2026 02:32:00 GMTFiserv Is Maintained at Outperform by RBC Capital - MoomooMoomoo · Fri, 07 Aug 2026 19:34:00 GMTRBC Capital Adjusts Price Target on Dana to $37 From $33, Maintains Outperform Rating - MoomooMoomoo · Fri, 07 Aug 2026 11:00:57 GMTRBC Capital Adjusts Price Target on Dynatrace to $59 From $50, Maintains Outperform Rating - MoomooMoomoo · Fri, 07 Aug 2026 10:19:05 GMTRBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4 - MoomooMoomoo · Thu, 06 Aug 2026 20:01:57 GMTNNN REIT Is Maintained at Sector Perform by RBC Capital - MoomooMoomoo · Thu, 06 Aug 2026 17:53:00 GMTRBC Capital Adjusts Price Target on Zimmer Biomet to $110 From $101, Maintains Outperform Rating - MoomooMoomoo · Thu, 06 Aug 2026 14:39:40 GMTRBC Capital Maintains Mobility Global(MBGL.US) With Hold Rating, Maintains Target Price $23 - MoomooMoomoo · Thu, 06 Aug 2026 11:34:00 GMT